Paris, December 21, 2021 – UGGC Avocats, a leading business law firm, has advised Therinvest on the investment in convertible bonds by Biogen, a neuroscience pioneer, in Therapanacea, which specialises in information technology to stimulate innovation in healthcare.
Therinvest is a family-owned investment fund created in 2018 that aims to support entrepreneurs with ambitious projects in the fields of healthcare and new technologies in order to foster the growth of French HealthTech companies.
The UGGC Avocats team that accompanied Therinvest was composed of:
- Ali Bougrine (partner)
- Carole Fouldrin (associate)
Other advisors involved in the transaction
Thomas Saltiel (partner) of Joffe & Associés advised Therapanacea, while Olivier Chambord (partner) with Morgan Lewis advised Biogen.
About UGGC Avocats
Founded in 1993, UGGC Avocats is one of the leading independent business law firms in France. UGGC Avocats assists private and public operators. The firm has extensive expertise in legal and tax matters; through its teams and its “family office”, it offers a very large capacity of intervention in France and internationally (Europe, Africa, Asia and South America). UGGC Avocats is positioned as a “client firm” and its approach is based on its ability to mobilize multidisciplinary teams adapted to its clients’ needs. UGGC Avocats is composed of more than 170 lawyers and legal advisors around the world.
Media contacts
Marine Dahais mdahais@golinfrance.fr +33 7 60 54 00 25
Camille Guaine cguaine@golinfrance.fr +33 7 60 54 00 39
Anne Da Silva Passos adasilvapassos@golinfrance.fr +33 7 60 53 99 28
